Danish biotechnology company NeuroSearch A/S (CPH:NEUR) confirmed on Thursday that it is in discussions with regard to the potential sale of its rights to Pridopidine for a small seven figure amount in DKK.

This is with reference to the article in MedWatch on 19 April 2018 relating to Teva giving up the development of the investigational medicinal product, Pridopidine.

NeuroSearch added that it is still investigating the potential sale of the company, but there is no certainty that these investigations will result in such a sale.

NeuroSearch will provide further information if and when required to do so.

Neurosearch specialises in pharmaceuticals for treating diseases and disorders affecting the central nervous system.